AR and prostate cancer: Conteduca Conteduca V V Wetterskog Wetterskog D D Sharabiani Sharabiani MTA MTA Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study Ann Oncol Ann Oncol 2017 2017 28 28 1508 1508 1516 1516 supplied-pmid 28472366?